Zacks Research Has Weak Forecast for OPKO Health Q3 Earnings

OPKO Health, Inc. (NASDAQ:OPK) – Zacks Research dropped their Q3 2026 earnings estimates for shares of OPKO Health in a report released on Thursday, March 19th. Zacks Research analyst Team now expects that the biotechnology company will post earnings per share of ($0.07) for the quarter, down from their prior estimate of ($0.06). The consensus estimate for OPKO Health’s current full-year earnings is ($0.25) per share. Zacks Research also issued estimates for OPKO Health’s Q4 2026 earnings at ($0.07) EPS, FY2026 earnings at ($0.29) EPS, Q1 2027 earnings at ($0.07) EPS, Q2 2027 earnings at ($0.07) EPS, Q3 2027 earnings at ($0.08) EPS, Q4 2027 earnings at ($0.08) EPS and FY2027 earnings at ($0.29) EPS.

OPK has been the subject of several other reports. Weiss Ratings reissued a “sell (d-)” rating on shares of OPKO Health in a research note on Thursday, January 22nd. Barrington Research lowered their target price on OPKO Health from $2.25 to $1.50 and set an “outperform” rating on the stock in a research note on Monday, March 2nd. Finally, Wall Street Zen downgraded OPKO Health from a “hold” rating to a “sell” rating in a report on Saturday, March 7th. One analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $2.03.

OPKO Health Stock Performance

Shares of OPK stock opened at $1.15 on Monday. OPKO Health has a 1-year low of $1.10 and a 1-year high of $1.83. The company has a current ratio of 3.97, a quick ratio of 3.52 and a debt-to-equity ratio of 0.26. The company has a market capitalization of $872.93 million, a price-to-earnings ratio of -3.83 and a beta of 1.50. The stock’s fifty day simple moving average is $1.23 and its 200-day simple moving average is $1.33.

OPKO Health (NASDAQ:OPK) last announced its earnings results on Thursday, February 26th. The biotechnology company reported ($0.04) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.07) by $0.03. The company had revenue of $148.50 million for the quarter, compared to the consensus estimate of $139.76 million. OPKO Health had a negative net margin of 37.19% and a negative return on equity of 17.42%. The company’s revenue was down 19.1% on a year-over-year basis. During the same period in the previous year, the business earned $0.01 EPS.

Institutional Trading of OPKO Health

A number of institutional investors have recently bought and sold shares of OPK. Caprock Group LLC acquired a new position in OPKO Health in the 3rd quarter worth about $26,000. Swiss Life Asset Management Ltd acquired a new stake in shares of OPKO Health during the 3rd quarter valued at about $30,000. Zacks Investment Management acquired a new stake in shares of OPKO Health during the 4th quarter valued at about $27,000. Savant Capital LLC bought a new stake in shares of OPKO Health in the 3rd quarter valued at approximately $33,000. Finally, StoneX Group Inc. bought a new stake in shares of OPKO Health in the 4th quarter valued at approximately $27,000. Institutional investors and hedge funds own 64.63% of the company’s stock.

About OPKO Health

OPKO Health, Inc (NASDAQ:OPK) is a diversified, global healthcare company headquartered in Miami, Florida, with a focus on diagnostics, pharmaceuticals and biologics development. The company operates two main business segments—Laboratory Services and Pharma Services & Products—driven by its mission to advance patient care through innovation in testing and targeted therapies.

In its Laboratory Services segment, OPKO leverages BioReference Laboratories, one of the largest full-service commercial labs in the United States.